Biomedical Advances in ABCA1 Transporter: From Bench to Bedside
Open Access
- 15 February 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 561
Abstract
ATP-binding cassette transporter A1 (ABCA1) has been identified as the molecular defect in Tangier disease. It is biochemically characterized by absence of high-density lipoprotein cholesterol (HDL-C) in the circulation, resulting in the accumulation of cholesterol in lymphoid tissues. Accumulation of cholesterol in arteries is an underlying cause of atherosclerosis, and HDL-C levels are inversely associated with the presence of atherosclerotic cardiovascular disease (ASCVD). ABCA1 increases HDL-C levels by driving the generation of new HDL particles in cells, and cellular cholesterol is removed in the process of HDL generation. Therefore, pharmacological strategies that promote the HDL biogenic process by increasing ABCA1 expression and activity have been intensively studied to reduce ASCVD. Many ABCA1-upregulating agents have been developed, and some have shown promising effects in pre-clinical studies, but no clinical trials have met success yet. ABCA1 has long been an attractive drug target, but the failed clinical trials have indicated the difficulty of therapeutic upregulation of ABCA1, as well as driving us to: improve our understanding of the ABCA1 regulatory system; to develop more specific and sophisticated strategies to upregulate ABCA1 expression; and to search for novel druggable targets in the ABCA1-dependent HDL biogenic process. In this review, we discuss the beginning, recent advances, challenges and future directions in ABCA1 research aimed at developing ABCA1-directed therapies for ASCVD.Keywords
Funding Information
- the Canadian Institutes of Health Research (PJT-165924)
This publication has 70 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- The Role of Endoplasmic Reticulum Stress in the Progression of AtherosclerosisCirculation Research, 2010
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesisJournal of Lipid Research, 2009
- The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low dosesBreast Cancer Research and Treatment, 2009
- ABCA1-Induced Cell Surface Binding Sites for ApoA-IArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Helical Apolipoproteins Stabilize ATP-binding Cassette Transporter A1 by Protecting It from Thiol Protease-mediated DegradationJournal of Biological Chemistry, 2002